Pan Bioscience Profile
Key Indicators
- Authorised Capital ₹ 0.70 M
- Paid Up Capital ₹ 0.60 M
- Company Age 14 Year, 9 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 1.56 M
- Revenue Growth -50.84%
- Profit Growth -260.97%
- Ebitda -394.64%
- Net Worth -48.88%
- Total Assets 18.33%
About Pan Bioscience
Pan Bioscience Private Limited (PBPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 May 2010 and has a history of 14 years and nine months. Its registered office is in Chennai, Tamil Nadu, India.
The Corporate was formerly known as Mylab Diagnostics Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.70 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹1.56 M.
Ashok Sharma and Aashish Sharma serve as directors at the Company.
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U93000TN2010PTC075826
- Company No.
075826
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 May 2010
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Pan Bioscience?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Sharma  | Director | 24-Aug-2018 | Current |
| Aashish Sharma | Director | 25-Feb-2019 | Current |
Financial Performance of Pan Bioscience.
Pan Bioscience Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 50.84% decrease. The company also saw a substantial fall in profitability, with a 260.97% decrease in profit. The company's net worth observed a substantial decline by a decrease of 48.88%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pan Bioscience?
In 2020, Pan Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.56 M
₹0
Charges Breakdown by Lending Institutions
- Corporation Bank : 0.16 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Aug 2015 | Corporation Bank | ₹1.56 M | Open |
How Many Employees Work at Pan Bioscience?
Unlock and access historical data on people associated with Pan Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pan Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pan Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
